Pharmacological inhibition of TGF-β receptor 1 in the tumor microenvironment using TGF-βR1-specific inhibitor LY2157299 prevented metastasis formation and disease progression in patient-derived tumor organoids, which further warrants investigating TGF-β inhibition in patients with poor-prognosis CRC [57]. The gene discussed is TGFB1; the disease is neoplasm.